{"success":true,"data":{"pressRelease":{"id":"161255","rtpr_id":"nPre9X1N2a-20261006","ticker":"HLUNA","exchange":"Nasdaq Copenhagen","all_tickers":["HLUNA"],"title":"Lundbeck presents Phase Ib data for Lu AF28996 in advanced Parkinson's disease, as Phase II trial begins","author":"PR Newswire","published_at":"2026-10-06T06:19:44.489Z","article_body":"Lundbeck presents Phase Ib data for Lu AF28996 in advanced Parkinson's\ndisease, as Phase II trial begins\nPR Newswire\n\nVALBY, Denmark, Oct. 6, 2026\n* Results from an 18-week, open-label Phase Ib trial of investigational Lu\nAF28996 in people with advanced Parkinson's disease are being presented at MDS\n2026\n* The trial provided initial safety and tolerability data for Lu AF28996, with\nmost treatment-emergent adverse events reported as mild\n* Descriptive changes from baseline in motor fluctuations were observed with\nLu AF28996, including increases in Good ON-time and reductions in OFF-time,\nalongside reductions in dyskinesia severity\n* Phase II development of Lu AF28996 is underway, with the first patient\nrandomized in the DARE2 trial¹\nVALBY, Denmark, Oct. 6, 2026 /PRNewswire/ -- H. Lundbeck A/S (Lundbeck) today\nannounced results from an open-label Phase Ib trial evaluating Lu AF28996, a\nnovel, investigational, oral prodrug of D1-like/D2-like dopamine receptor\nagonist, in people with advanced Parkinson's disease experiencing motor\nsymptoms sub-optimally controlled despite optimized non-invasive\nantiparkinsonian medication. The results are being presented at the\nInternational Congress of Parkinson's Disease and Movement Disorders® (MDS)\n2026 in Seoul, South Korea.\n\nParkinson's disease is characterized by the progressive degeneration of\ndopamine-producing neurons in the brain.(2) While levodopa remains the\ncornerstone of symptomatic treatment, many people experience\ndifficult-to-manage motor complications as the disease progresses.(3,4) These\ninclude fluctuations between periods of good symptom control (\"ON-time\") and\nperiods when symptoms return or worsen (\"OFF-time\"), and treatment-related\ndyskinesia (involuntary movements) despite optimized treatment.(3 )For people\nwith advanced Parkinson's disease, many treatment options involve invasive\nprocedures or continuous drug delivery, requiring patients to meet specific\neligibility criteria.(4,5) There remains a need for effective, well-tolerated\nand non-invasive treatment approaches that can provide more consistent motor\ncontrol.\n\n\"Many people with advanced Parkinson's disease continue to experience motor\nfluctuations and dyskinesia that can significantly affect daily life,\" said\nTarek Samad, Executive Vice President and Head of Research & Development at\nLundbeck. \"We are encouraged by the Phase Ib results with Lu AF28996,\nincluding the improvements observed alongside substantial reductions in\nlevodopa dose. With the DARE2 Phase II trial now underway, we are taking the\nnext step in evaluating its potential in a larger, randomized and controlled\nstudy.\"\n\nPhase Ib results\nNCT04291859 comprised Part A once- and twice-daily ascending-dose cohorts and\nPart B twice-daily cohorts B1–B3. The MDS 2026 presentation and this release\nreport results from Part B. In Part B of the trial, 34 participants received\nLu AF28996 twice daily for six weeks.(6) Eligible participants could continue\nin an optional extension period of up to 12 additional weeks, and 25\nparticipants elected to enter the extension.\n\nDuring the trial, most treatment-emergent adverse events were considered mild.\nNo unexpected safety signals were observed, and the safety profile was\nconsistent with a dopaminergic mechanism of action of Lu AF28996. The most\ncommon treatment-emergent adverse events were nausea, dizziness, and falls.\n\nAt baseline, participants experienced a mean of 9.5 hours of Good ON-time\n(ON-time without troublesome dyskinesia), 4.7 hours of OFF-time, and 1.8 hours\nof ON-time with troublesome dyskinesia per day. At Weeks 6 and 18,\nrespectively, Good ON-time increased from baseline by 3.6 and 3.4 hours,\nOFF-time decreased by 2.3 and 2.0 hours, and ON-time with troublesome\ndyskinesia decreased by 1.2 and 1.4 hours.\n\nThese changes were accompanied by reductions from baseline in dyskinesia\nseverity, as measured by the Unified Dyskinesia Rating Scale (UDysRS) total\nscore, of 8.5 points at Week 6 and 14.5 points at Week 18, from a baseline\nscore of 28.3 points. Reductions in mean daily levodopa dose were observed,\nwith reductions of 53.4% at Week 6 and 29.2% at Week 18.\n\nAmong participants with ≥1 hour/day of troublesome dyskinesia at baseline,\nmean changes from baseline in daily ON-time with troublesome dyskinesia were\n−2.3 hours per day at Week 6 and −2.8 hours at Week 18.\n\nThe trial was exploratory, involved a limited number of participants and did\nnot include a placebo or active comparator. The findings are to be further\nexplored in the larger, randomized and controlled DARE2 trial.\n\nThe Phase II DARE2 trial\nDARE2 (NCT07514858) is a Phase II randomized, double-blind, parallel-group,\nplacebo-controlled, flexible-dose trial evaluating Lu AF28996 in approximately\n150 adults with Parkinson's disease who continue to experience motor\nfluctuations despite optimized non-invasive symptomatic treatment.(1) The\nprimary endpoint is change from baseline to Week 19 in daily Good ON-time.(1)\n\nThe first participant in DARE2 has been randomized, and recruitment is\nunderway at selected sites in the United States. Additional sites are planned\nin the United Kingdom, Spain, Italy, Germany, France, Poland, the Czech\nRepublic, Sweden and Japan. Current site information is available on\nClinicalTrials.gov\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4790485-1&h=1685859662&u=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT07514858%3Fcond%3DNCT07514858%26viewType%3DCard%26rank%3D1&a=ClinicalTrials.gov).(1)\n\nLu AF28996 is not approved by the US Food and Drug Administration (FDA) or any\nother regulatory agency, and the efficacy and safety of Lu AF28996 have not\nbeen established. \n\nAbout Parkinson's disease\nParkinson's disease (PD) is a progressive and disabling neurological disease\ncharacterized by motor symptoms including slowness of movement, tremor and\nrigidity, as well as a range of non-motor symptoms.(4,5) There are currently\nno established treatments that modify the progression of PD, and levodopa\nremains a cornerstone of symptomatic treatment.(2,4 )With long-term levodopa\ntreatment, many people develop motor complications, including periods when\nsymptoms return or worsen (\"OFF-time\") and dyskinesia (involuntary movements),\nwhich can significantly affect daily functioning and quality of life.(2-5 )\n\nPD is the second most common neurodegenerative disease after Alzheimer's\ndisease and the most common movement disorder.(7,8) In 2021, an estimated\n11.77 million people worldwide were living with PD, and its prevalence is\nprojected to more than double by 2050.(8,9 )As PD progresses, functional\nindependence can decline and reliance on caregivers and healthcare systems can\nincrease, contributing to a substantial personal, societal and economic\nburden.\n\nAbout Lu AF28996\nLu AF28996 is an investigational, novel and oral prodrug of a D1-like/D2-like\ndopamine receptor agonist, with a pharmacologic profile that may enhance\ndopaminergic striatal signaling in a prolonged manner. It is being\ninvestigated for its potential to improve motor fluctuations and\nlevodopa-induced dyskinesia in people with Parkinson's disease. Concerted\nactivation of D1- and D2-like dopamine receptors may play an important role in\nmotor control.(10)\n\nLu AF28996 is not approved by the US Food and Drug Administration (FDA) or any\nother regulatory agency, and the efficacy and safety of Lu AF28996 have not\nbeen established. \n\nAbout NCT04291859\nNCT04291859 was an open-label Phase Ib trial evaluating the safety,\ntolerability and clinical effects of Lu AF28996 in people with advanced\nParkinson's disease experiencing motor fluctuations, with or without\ndyskinesia, despite non-invasive antiparkinsonian medication.\n\nThirty-four participants received Lu AF28996 twice daily for six weeks,\nfollowed by an optional extension period of up to 12 weeks. Twenty-five\neligible participants elected to enter the extension period.\n\nThe trial was exploratory, involved a limited number of participants and did\nnot include a placebo or active comparator. The findings require confirmation\nin larger, randomized and controlled clinical trials.\n\nContacts\n\nAnders Crillesen\nSenior Director, External & Internal Relations\nAECE@lundbeck.com\n+45 27 79 12 86\n\nJens Høyer \nVice President, Head of Investor Relations\nJSHR@lundbeck.com\n+45 30 83 45 01\n\nAbout H. Lundbeck A/S\nLundbeck is a biopharmaceutical company focusing exclusively on brain health.\nWith more than 70 years of experience in neuroscience, we are committed to\nimproving the lives of people with neurological and psychiatric diseases.\n\nBrain disorders affect a large part of the world's population, and the effects\nare felt throughout society. With the rapidly improving understanding of the\nbiology of the brain, we hold ourselves accountable for advancing brain health\nby curiously exploring new opportunities for treatments.\n\nAs a focused innovator, we strive for our research and development programs to\ntackle some of the most complex neurological challenges. We develop\ntransformative medicines targeting people for whom there are few or no\ntreatments available, expanding into neuro-specialty and neuro-rare from our\nstrong legacy within psychiatry and neurology.\n\nWe are committed to fighting stigma and we act to improve health equity. We\nstrive to create long term value for our shareholders by making a positive\ncontribution to patients, their families and society as a whole.\n\nLundbeck has more than 5,000 employees in more than 20 countries and our\nproducts are available in more than 80 countries. For additional information,\nwe encourage you to visit our corporate site www.lundbeck.com and connect with\nus via LinkedIn\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4790485-1&h=3918534933&u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Flundbeck%2F&a=LinkedIn).\n\nReferences:\n1.\nhttps://clinicaltrials.gov/study/NCT07514858?term=nct07514858%20&viewType=Card&rank=1\n2. Kalia LV, Lang AE. Parkinson's disease. Lancet 2015;386:896–912\n3. Cenci MA. Front Neurol 2014;5:242\n4. Stocchi F, et al. Nat Rev Neurol 2024;20:695–707\n5. Heim B and Poewe W. J Parkinsons Dis 2025;16(2_suppl):24-37\n6. Højer AM, et al. Poster presentation at International Congress of\nParkinson's Disease and Movement Disorders® (MDS) 2026\n7. GBD. Global, regional, and national burden of neurological disorders during\n1990-2015: a systematic analysis for the Global Burden of Disease Study 2015.\nLancet Neurol 2017;16:877–897\n8. Luo Y, et al. Front Aging Neurosci 2025;16:1498756\n9. Su D et al. BMJ. 2025;388:e080952\n10. Isaacson SH, et al. Clin Park Relat Disord. 2023;9:100212 \nThis information was brought to you by Cision http://news.cision.com\n\nhttps://news.cision.com/h--lundbeck-a-s/r/lundbeck-presents-phase-ib-data-for-lu-af28996-in-advanced-parkinson-s-disease--as-phase-ii-trial-be,c4404133\n\nThe following files are available for download:\n\n https://mb.cision.com/Main/18215/4404133/4300364.pdf  DART2G Final  \n\n \n\nView original\ncontent:https://www.prnewswire.co.uk/news-releases/lundbeck-presents-phase-ib-data-for-lu-af28996-in-advanced-parkinsons-disease-as-phase-ii-trial-begins-302899419.html\n\n\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPre9X1N2a-20261006","title":"Lundbeck presents Phase Ib data for Lu AF28996 in advanced Parkinson's disease, as Phase II trial begins","author":"PR Newswire","ticker":"HLUNA","created":"2026-10-06T06:19:44.489Z","tickers":["HLUNA"],"exchange":"Nasdaq Copenhagen","article_body":"Lundbeck presents Phase Ib data for Lu AF28996 in advanced Parkinson's\ndisease, as Phase II trial begins\nPR Newswire\n\nVALBY, Denmark, Oct. 6, 2026\n* Results from an 18-week, open-label Phase Ib trial of investigational Lu\nAF28996 in people with advanced Parkinson's disease are being presented at MDS\n2026\n* The trial provided initial safety and tolerability data for Lu AF28996, with\nmost treatment-emergent adverse events reported as mild\n* Descriptive changes from baseline in motor fluctuations were observed with\nLu AF28996, including increases in Good ON-time and reductions in OFF-time,\nalongside reductions in dyskinesia severity\n* Phase II development of Lu AF28996 is underway, with the first patient\nrandomized in the DARE2 trial¹\nVALBY, Denmark, Oct. 6, 2026 /PRNewswire/ -- H. Lundbeck A/S (Lundbeck) today\nannounced results from an open-label Phase Ib trial evaluating Lu AF28996, a\nnovel, investigational, oral prodrug of D1-like/D2-like dopamine receptor\nagonist, in people with advanced Parkinson's disease experiencing motor\nsymptoms sub-optimally controlled despite optimized non-invasive\nantiparkinsonian medication. The results are being presented at the\nInternational Congress of Parkinson's Disease and Movement Disorders® (MDS)\n2026 in Seoul, South Korea.\n\nParkinson's disease is characterized by the progressive degeneration of\ndopamine-producing neurons in the brain.(2) While levodopa remains the\ncornerstone of symptomatic treatment, many people experience\ndifficult-to-manage motor complications as the disease progresses.(3,4) These\ninclude fluctuations between periods of good symptom control (\"ON-time\") and\nperiods when symptoms return or worsen (\"OFF-time\"), and treatment-related\ndyskinesia (involuntary movements) despite optimized treatment.(3 )For people\nwith advanced Parkinson's disease, many treatment options involve invasive\nprocedures or continuous drug delivery, requiring patients to meet specific\neligibility criteria.(4,5) There remains a need for effective, well-tolerated\nand non-invasive treatment approaches that can provide more consistent motor\ncontrol.\n\n\"Many people with advanced Parkinson's disease continue to experience motor\nfluctuations and dyskinesia that can significantly affect daily life,\" said\nTarek Samad, Executive Vice President and Head of Research & Development at\nLundbeck. \"We are encouraged by the Phase Ib results with Lu AF28996,\nincluding the improvements observed alongside substantial reductions in\nlevodopa dose. With the DARE2 Phase II trial now underway, we are taking the\nnext step in evaluating its potential in a larger, randomized and controlled\nstudy.\"\n\nPhase Ib results\nNCT04291859 comprised Part A once- and twice-daily ascending-dose cohorts and\nPart B twice-daily cohorts B1–B3. The MDS 2026 presentation and this release\nreport results from Part B. In Part B of the trial, 34 participants received\nLu AF28996 twice daily for six weeks.(6) Eligible participants could continue\nin an optional extension period of up to 12 additional weeks, and 25\nparticipants elected to enter the extension.\n\nDuring the trial, most treatment-emergent adverse events were considered mild.\nNo unexpected safety signals were observed, and the safety profile was\nconsistent with a dopaminergic mechanism of action of Lu AF28996. The most\ncommon treatment-emergent adverse events were nausea, dizziness, and falls.\n\nAt baseline, participants experienced a mean of 9.5 hours of Good ON-time\n(ON-time without troublesome dyskinesia), 4.7 hours of OFF-time, and 1.8 hours\nof ON-time with troublesome dyskinesia per day. At Weeks 6 and 18,\nrespectively, Good ON-time increased from baseline by 3.6 and 3.4 hours,\nOFF-time decreased by 2.3 and 2.0 hours, and ON-time with troublesome\ndyskinesia decreased by 1.2 and 1.4 hours.\n\nThese changes were accompanied by reductions from baseline in dyskinesia\nseverity, as measured by the Unified Dyskinesia Rating Scale (UDysRS) total\nscore, of 8.5 points at Week 6 and 14.5 points at Week 18, from a baseline\nscore of 28.3 points. Reductions in mean daily levodopa dose were observed,\nwith reductions of 53.4% at Week 6 and 29.2% at Week 18.\n\nAmong participants with ≥1 hour/day of troublesome dyskinesia at baseline,\nmean changes from baseline in daily ON-time with troublesome dyskinesia were\n−2.3 hours per day at Week 6 and −2.8 hours at Week 18.\n\nThe trial was exploratory, involved a limited number of participants and did\nnot include a placebo or active comparator. The findings are to be further\nexplored in the larger, randomized and controlled DARE2 trial.\n\nThe Phase II DARE2 trial\nDARE2 (NCT07514858) is a Phase II randomized, double-blind, parallel-group,\nplacebo-controlled, flexible-dose trial evaluating Lu AF28996 in approximately\n150 adults with Parkinson's disease who continue to experience motor\nfluctuations despite optimized non-invasive symptomatic treatment.(1) The\nprimary endpoint is change from baseline to Week 19 in daily Good ON-time.(1)\n\nThe first participant in DARE2 has been randomized, and recruitment is\nunderway at selected sites in the United States. Additional sites are planned\nin the United Kingdom, Spain, Italy, Germany, France, Poland, the Czech\nRepublic, Sweden and Japan. Current site information is available on\nClinicalTrials.gov\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4790485-1&h=1685859662&u=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT07514858%3Fcond%3DNCT07514858%26viewType%3DCard%26rank%3D1&a=ClinicalTrials.gov).(1)\n\nLu AF28996 is not approved by the US Food and Drug Administration (FDA) or any\nother regulatory agency, and the efficacy and safety of Lu AF28996 have not\nbeen established. \n\nAbout Parkinson's disease\nParkinson's disease (PD) is a progressive and disabling neurological disease\ncharacterized by motor symptoms including slowness of movement, tremor and\nrigidity, as well as a range of non-motor symptoms.(4,5) There are currently\nno established treatments that modify the progression of PD, and levodopa\nremains a cornerstone of symptomatic treatment.(2,4 )With long-term levodopa\ntreatment, many people develop motor complications, including periods when\nsymptoms return or worsen (\"OFF-time\") and dyskinesia (involuntary movements),\nwhich can significantly affect daily functioning and quality of life.(2-5 )\n\nPD is the second most common neurodegenerative disease after Alzheimer's\ndisease and the most common movement disorder.(7,8) In 2021, an estimated\n11.77 million people worldwide were living with PD, and its prevalence is\nprojected to more than double by 2050.(8,9 )As PD progresses, functional\nindependence can decline and reliance on caregivers and healthcare systems can\nincrease, contributing to a substantial personal, societal and economic\nburden.\n\nAbout Lu AF28996\nLu AF28996 is an investigational, novel and oral prodrug of a D1-like/D2-like\ndopamine receptor agonist, with a pharmacologic profile that may enhance\ndopaminergic striatal signaling in a prolonged manner. It is being\ninvestigated for its potential to improve motor fluctuations and\nlevodopa-induced dyskinesia in people with Parkinson's disease. Concerted\nactivation of D1- and D2-like dopamine receptors may play an important role in\nmotor control.(10)\n\nLu AF28996 is not approved by the US Food and Drug Administration (FDA) or any\nother regulatory agency, and the efficacy and safety of Lu AF28996 have not\nbeen established. \n\nAbout NCT04291859\nNCT04291859 was an open-label Phase Ib trial evaluating the safety,\ntolerability and clinical effects of Lu AF28996 in people with advanced\nParkinson's disease experiencing motor fluctuations, with or without\ndyskinesia, despite non-invasive antiparkinsonian medication.\n\nThirty-four participants received Lu AF28996 twice daily for six weeks,\nfollowed by an optional extension period of up to 12 weeks. Twenty-five\neligible participants elected to enter the extension period.\n\nThe trial was exploratory, involved a limited number of participants and did\nnot include a placebo or active comparator. The findings require confirmation\nin larger, randomized and controlled clinical trials.\n\nContacts\n\nAnders Crillesen\nSenior Director, External & Internal Relations\nAECE@lundbeck.com\n+45 27 79 12 86\n\nJens Høyer \nVice President, Head of Investor Relations\nJSHR@lundbeck.com\n+45 30 83 45 01\n\nAbout H. Lundbeck A/S\nLundbeck is a biopharmaceutical company focusing exclusively on brain health.\nWith more than 70 years of experience in neuroscience, we are committed to\nimproving the lives of people with neurological and psychiatric diseases.\n\nBrain disorders affect a large part of the world's population, and the effects\nare felt throughout society. With the rapidly improving understanding of the\nbiology of the brain, we hold ourselves accountable for advancing brain health\nby curiously exploring new opportunities for treatments.\n\nAs a focused innovator, we strive for our research and development programs to\ntackle some of the most complex neurological challenges. We develop\ntransformative medicines targeting people for whom there are few or no\ntreatments available, expanding into neuro-specialty and neuro-rare from our\nstrong legacy within psychiatry and neurology.\n\nWe are committed to fighting stigma and we act to improve health equity. We\nstrive to create long term value for our shareholders by making a positive\ncontribution to patients, their families and society as a whole.\n\nLundbeck has more than 5,000 employees in more than 20 countries and our\nproducts are available in more than 80 countries. For additional information,\nwe encourage you to visit our corporate site www.lundbeck.com and connect with\nus via LinkedIn\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4790485-1&h=3918534933&u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Flundbeck%2F&a=LinkedIn).\n\nReferences:\n1.\nhttps://clinicaltrials.gov/study/NCT07514858?term=nct07514858%20&viewType=Card&rank=1\n2. Kalia LV, Lang AE. Parkinson's disease. Lancet 2015;386:896–912\n3. Cenci MA. Front Neurol 2014;5:242\n4. Stocchi F, et al. Nat Rev Neurol 2024;20:695–707\n5. Heim B and Poewe W. J Parkinsons Dis 2025;16(2_suppl):24-37\n6. Højer AM, et al. Poster presentation at International Congress of\nParkinson's Disease and Movement Disorders® (MDS) 2026\n7. GBD. Global, regional, and national burden of neurological disorders during\n1990-2015: a systematic analysis for the Global Burden of Disease Study 2015.\nLancet Neurol 2017;16:877–897\n8. Luo Y, et al. Front Aging Neurosci 2025;16:1498756\n9. Su D et al. BMJ. 2025;388:e080952\n10. Isaacson SH, et al. Clin Park Relat Disord. 2023;9:100212 \nThis information was brought to you by Cision http://news.cision.com\n\nhttps://news.cision.com/h--lundbeck-a-s/r/lundbeck-presents-phase-ib-data-for-lu-af28996-in-advanced-parkinson-s-disease--as-phase-ii-trial-be,c4404133\n\nThe following files are available for download:\n\n https://mb.cision.com/Main/18215/4404133/4300364.pdf  DART2G Final  \n\n \n\nView original\ncontent:https://www.prnewswire.co.uk/news-releases/lundbeck-presents-phase-ib-data-for-lu-af28996-in-advanced-parkinsons-disease-as-phase-ii-trial-begins-302899419.html\n\n\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-10-06T06:19:44.538180444Z","server_sent_at_ms":1791267584538},"received_at":"2026-10-06T06:19:44.589Z","source_url":null},"analysis":{"id":"149794","press_release_id":"161255","analysis_json":{"industry":{"label":"Pharmaceuticals","sector":"Health Care"},"redFlags":["Phase Ib was open-label, exploratory, small (n=34) and had no placebo or active comparator","Lu AF28996 is investigational and not approved by any regulatory agency"],"eventType":"clinical_trial","narrative":"Lundbeck presented Phase Ib data for Lu AF28996, an investigational oral dopamine receptor agonist prodrug, in advanced Parkinson's disease at the MDS 2026 congress.\n\nIn the 34-participant open-label Part B, Good ON-time rose 3.6 hours at Week 6 and OFF-time fell 2.3 hours, with dyskinesia severity reductions and most adverse events rated mild.\n\nThe first patient has been randomized in the Phase II DARE2 trial (NCT07514858), a placebo-controlled study of ~150 adults with motor fluctuations, with US recruitment underway and additional sites planned across Europe and Japan.\n\nLu AF28996 is not approved by the FDA or any regulator, and the exploratory, uncontrolled Phase Ib design means findings require confirmation in DARE2.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Encouraging open-label Phase Ib signals for Lundbeck's Parkinson's pipeline asset as the pivotal Phase II DARE2 trial starts enrollment."},"keyFigures":{"drugName":"Lu AF28996","phaseOfTrial":"Phase Ib (Part B); Phase II DARE2 initiated","customDimensions":{"participants_phase1b":34,"extension_participants":25,"dare2_planned_enrollment":150,"good_ontime_gain_week6_hours":3.6,"good_ontime_gain_week18_hours":3.4,"offtime_reduction_week6_hours":2.3,"offtime_reduction_week18_hours":2,"udysrs_reduction_week18_points":14.5,"levodopa_dose_reduction_week18_pct":"29.2%"}},"quotedText":"We are encouraged by the Phase Ib results with Lu AF28996, including the improvements observed alongside substantial reductions in levodopa dose.","namedEntities":{"people":[{"name":"Tarek Samad","role":"Executive Vice President and Head of Research & Development, Lundbeck"},{"name":"Anders Crillesen","role":"Senior Director, External & Internal Relations"},{"name":"Jens Høyer","role":"Vice President, Head of Investor Relations"}],"products":["Lu AF28996"],"companies":[{"name":"H. Lundbeck A/S","ticker":"HLUNA","relationship":"filer/issuer"}],"dollarAmounts":[]},"materialImpact":{"score":3,"reasoning":"Positive exploratory Phase Ib data (no placebo control, n=34) for pipeline asset Lu AF28996, with Phase II DARE2 trial now randomized/recruiting. Encouraging but early-stage; not a binary event."},"tickerRelevance":{"others":[],"primary":"HLUNA"},"globalImportance":35,"audienceRelevance":25,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap foreign issuer (ADR)","eventGravity":"early-stage positive pipeline data + Phase II start","sectorWeight":"neuroscience-focused pharma, meaningful unmet need in Parkinson's","dataQualityLimitation":"open-label, no comparator"}},"event_type":"clinical_trial","event_type_secondary":null,"sentiment":"bullish","material_impact_score":3,"narrative":"Lundbeck presented Phase Ib data for Lu AF28996, an investigational oral dopamine receptor agonist prodrug, in advanced Parkinson's disease at the MDS 2026 congress.\n\nIn the 34-participant open-label Part B, Good ON-time rose 3.6 hours at Week 6 and OFF-time fell 2.3 hours, with dyskinesia severity reductions and most adverse events rated mild.\n\nThe first patient has been randomized in the Phase II DARE2 trial (NCT07514858), a placebo-controlled study of ~150 adults with motor fluctuations, with US recruitment underway and additional sites planned across Europe and Japan.\n\nLu AF28996 is not approved by the FDA or any regulator, and the exploratory, uncontrolled Phase Ib design means findings require confirmation in DARE2.","key_figures":{"drugName":"Lu AF28996","phaseOfTrial":"Phase Ib (Part B); Phase II DARE2 initiated","customDimensions":{"participants_phase1b":34,"extension_participants":25,"dare2_planned_enrollment":150,"good_ontime_gain_week6_hours":3.6,"good_ontime_gain_week18_hours":3.4,"offtime_reduction_week6_hours":2.3,"offtime_reduction_week18_hours":2,"udysrs_reduction_week18_points":14.5,"levodopa_dose_reduction_week18_pct":"29.2%"}},"named_entities":{"people":[{"name":"Tarek Samad","role":"Executive Vice President and Head of Research & Development, Lundbeck"},{"name":"Anders Crillesen","role":"Senior Director, External & Internal Relations"},{"name":"Jens Høyer","role":"Vice President, Head of Investor Relations"}],"products":["Lu AF28996"],"companies":[{"name":"H. Lundbeck A/S","ticker":"HLUNA","relationship":"filer/issuer"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-06T06:19:51.470Z","global_importance":35,"audience_relevance":25,"importance_components":{"tickerTier":"mid-cap foreign issuer (ADR)","eventGravity":"early-stage positive pipeline data + Phase II start","sectorWeight":"neuroscience-focused pharma, meaningful unmet need in Parkinson's","dataQualityLimitation":"open-label, no comparator"}},"durationMs":6866,"modelName":"glm-5.3-flashx"}}